PLRX · Insider Trading
Pliant Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by PLRX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-02 | David Raben | Chief Medical Officer | A | +575,000 deriv. | — |
| 2026-07-13 | Flavia Borellini | Director | A | +60,000 deriv. | — |
| 2026-07-13 | Robert Iannone | Director | A | +60,000 deriv. | — |
| 2026-06-12 | Steve E. Krognes | Director | A | +70,000 deriv. | — |
| 2026-06-12 | Hoyoung Huh | Director | A | +70,000 deriv. | — |
| 2026-06-12 | Darren S Cline | Director | A | +70,000 deriv. | — |
| 2026-06-12 | Gayle A Crowell | Director | A | +70,000 deriv. | — |
| 2026-06-12 | John T Curnutte | Director | A | +70,000 deriv. | — |
| 2026-06-12 | Thomas A MCCOURT | Director | A | +70,000 deriv. | — |
| 2026-04-17 | Keith Lamont Cummings | Chief Financial Officer | MIXED | — | — |
| 2026-04-17 | Bernard Coulie | President and CEO | MIXED | — | — |
| 2026-04-17 | Lily Cheung | Chief Human Resource Officer | MIXED | — | — |
| 2026-04-17 | Minnie Kuo | Chief Operating Officer | MIXED | — | — |
| 2026-01-26 | Minnie Kuo | Chief Operating Officer | A | +300,000 deriv. | — |
| 2026-01-26 | Keith Lamont Cummings | Chief Financial Officer | A | +400,000 deriv. | — |
| 2026-01-26 | Bernard Coulie | President and CEO | A | +1,230,000 deriv. | — |
| 2026-01-26 | Lily Cheung | Chief Human Resource Officer | A | +300,000 deriv. | — |
| 2026-01-22 | Keith Lamont Cummings | Chief Financial Officer | Sell | −24,002 | −$30.72K |
| 2026-01-22 | Minnie Kuo | Chief Operating Officer | Sell | −6,917 | −$8.85K |
| 2026-01-22 | Lily Cheung | Chief Human Resource Officer | Sell | −7,534 | −$9.64K |
| 2026-01-22 | Bernard Coulie | President and CEO | Sell | −89,375 | −$114.40K |
| 2025-06-09 | Thomas A MCCOURT | Director | A | +30,000 deriv. | — |
| 2025-06-09 | Katharine Knobil | Director | A | +30,000 deriv. | — |
| 2025-06-09 | Suzanne Louise Bruhn | Director | A | +30,000 deriv. | — |
| 2025-06-09 | John T Curnutte | Director | A | +30,000 deriv. | — |
| 2025-06-09 | David E I Pyott | Director | A | +30,000 deriv. | — |
| 2025-06-09 | Hoyoung Huh | Director | A | +30,000 deriv. | — |
| 2025-06-09 | Steve E. Krognes | Director | A | +30,000 deriv. | — |
| 2025-06-09 | Darren S Cline | Director | A | +30,000 deriv. | — |
| 2025-06-09 | Gayle A Crowell | Director | A | +30,000 deriv. | — |
| 2025-01-27 | Lily Cheung | Chief Human Resource Officer | A | +25,875 | — |
| 2025-01-27 | Eric Lefebvre | Chief Medical Officer | A | +45,650 | — |
| 2025-01-27 | Hans Hull | Chief Business Officer | A | +40,150 | — |
| 2025-01-27 | Bernard Coulie | President and CEO | A | +162,500 | — |
| 2025-01-27 | Keith Lamont Cummings | Chief Financial Officer | A | +56,650 | — |
| 2025-01-27 | Mike Ouimette | General Counsel & Corp. Sec'y | A | +35,000 | — |
| 2025-01-22 | Lily Cheung | Chief Human Resource Officer | Sell | −3,740 | −$41.89K |
| 2025-01-22 | Eric Lefebvre | Chief Medical Officer | Sell | −18,478 | −$206.97K |
| 2025-01-22 | Keith Lamont Cummings | Chief Financial Officer | Sell | −20,148 | −$225.68K |
| 2025-01-22 | Bernard Coulie | President and CEO | Sell | −52,419 | −$587.15K |
| 2025-01-22 | Mike Ouimette | General Counsel & Corp. Sec'y | Sell | −23,500 | −$261.10K |
| 2025-01-22 | Hans Hull | Chief Business Officer | Sell | −15,936 | −$178.50K |
| 2024-07-12 | Mike Ouimette | General Counsel & Corp. Sec'y | Sell | −7,656 | −$88.50K |
| 2024-07-12 | Keith Lamont Cummings | Chief Financial Officer | Sell | −10,911 | −$126.13K |
| 2024-07-12 | Eric Lefebvre | Chief Medical Officer | Sell | −12,319 | −$142.41K |
| 2024-07-12 | Bernard Coulie | President and CEO | Sell | −38,710 | −$447.49K |
| 2024-07-12 | Hans Hull | Chief Business Officer | Sell | −9,900 | −$114.44K |
| 2024-07-11 | Mike Ouimette | General Counsel & Corp. Sec'y | A | +14,954 | — |
| 2024-07-11 | Hans Hull | Chief Business Officer | A | +19,337 | — |
| 2024-07-11 | Bernard Coulie | President and CEO | A | +75,625 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Bernard Coulie | President and CEO | 914,918 | $777.50K |
| Keith Lamont Cummings | Chief Financial Officer | 297,214 | $252.57K |
| Hans Hull | Chief Business Officer | 255,529 | $217.15K |
| Eric Lefebvre | Chief Medical Officer | 240,224 | $204.14K |
| Hoyoung Huh | Director | 239,619 | $203.63K |
| Mike Ouimette | General Counsel & Corp. Sec'y | 105,544 | $89.69K |
| Lily Cheung | Chief Human Resource Officer | 44,847 | $38.11K |
| Minnie Kuo | Chief Operating Officer | 37,806 | $32.13K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PLRX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.